{
    "clinical_study": {
        "@rank": "92297", 
        "acronym": "LGG BB-12", 
        "arm_group": [
            {
                "arm_group_label": "Probiotic group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention", 
                "description": "This is a non-supplemented control group that will follow the same dietary and medication restrictions.  The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure."
            }
        ], 
        "brief_summary": {
            "textblock": "The main hypothesis of this study is that there will be a significant increase of\n      Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis (BB-12) in the stool of healthy\n      humans following daily consumption of a probiotic supplement containing these specific\n      strains of probiotic bacteria."
        }, 
        "brief_title": "Fecal Recovery of the Probiotic Bacteria Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) in Healthy Humans Following Daily Consumption of a Probiotic Supplement", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Fecal Analysis", 
        "detailed_description": {
            "textblock": "To demonstrate recovery of live probiotic bacteria in the stool."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Are between 18-70 years of age. Have regular bowel movements. Are willing and able to\n        attend study visits, undergo limited blood and urine testing, take the nutritional\n        supplement according to the instructions provided.\n\n        Are willing to collect four stool specimens and bring them to the study site.\n\n        Exclusion Criteria:\n\n        Are unwilling to follow the dietary guidelines of the study. Are lactose-intolerant or\n        have allergies to milk or wheat. Have had drug or alcohol problems within the previous\n        year. Are or plan to become pregnant over the next 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757054", 
            "org_study_id": "B4141001", 
            "secondary_id": "PO-10-08"
        }, 
        "intervention": {
            "arm_group_label": "Probiotic group", 
            "description": "Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days", 
            "intervention_name": "ProNutrients Probiotic", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "probiotic", 
            "LGG", 
            "BB-12", 
            "fecal recovery", 
            "healthy subjects"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4141001&StudyName=Fecal%20recovery%20of%20the%20probiotic%20bacteria%20Lactobacillus%20rhamnosus%20GG%20%28LGG%29%20and%20Bifidobacterium%20Animalis%20subspecies%20Lactis%20BB-12%20%28BB-12%29"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02111"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Two Arm, Parallel Group, Open Label, Single Center Prospective Study of the Fecal Recovery of Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis (BB-12) in Healthy Humans Following Daily Consumption of ProNutrients Probiotic Powder Sachet", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pre- to post-supplementation changes in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR", 
            "measure": "Change in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR at baseline and 3 weeks", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757054"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pre- to post-supplementation changes in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR", 
                "measure": "Change in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR at baseline and 2 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2 weeks"
            }, 
            {
                "description": "Pre- to post-supplementation changes in fecal concentration of both LGG and BB-12 by quantitative PCR (qPCR)", 
                "measure": "Change in fecal concentration of both LGG and BB-12 by quantitative PCR (qPCR) at baseline and 3 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 weeks"
            }, 
            {
                "description": "Pre- to post-supplementation changes in fecal concentration of both LGG and BB-12 by quantitative PCR (qPCR)", 
                "measure": "Change in fecal concentration of both LGG and BB-12 by quantitative PCR (qPCR) at baseline and 2 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2 weeks"
            }, 
            {
                "description": "Pre- to post-supplementation changes in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR and qPCR in probiotic compared to control group", 
                "measure": "Change in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR and qPCR in probiotic compared to control group at baseline and 3 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 weeks"
            }, 
            {
                "description": "Pre- to post-supplementation changes in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR and qPCR in probiotic compared to control group", 
                "measure": "Change in fecal concentration of both LGG and BB-12 by quantitative culture with confirmatory PCR and qPCR in probiotic compared to control group at baseline and 2 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2 weeks"
            }, 
            {
                "description": "Post-supplementation fecal concentration of LGG and BB-12 by both quantitative culture with confirmatory PCR and qPCR compared to baseline and 3 week supplementation values", 
                "measure": "Change in fecal concentration of LGG and BB-12 by both quantitative culture with confirmatory PCR and qPCR at baseline, 3 weeks, and 28 days post supplementation", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 weeks, 28 days follow up"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}